Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report.

Autor: Nguyen OTD; Department of Oncology, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway.; Department of Clinical Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Sundstrøm SH; Department of Oncology, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway.; Department of Clinical Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Westvik GS; Department of Oncology, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Røttereng AKS; Department of Oncology, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Melhus MR; Department of Oncology, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Bergseth C; Department of Oncology, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Hallem EK; Department of Oncology, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Røe OD; Department of Oncology, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway.; Department of Clinical Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Publikováno v: Case reports in oncology [Case Rep Oncol] 2020 Sep 07; Vol. 13 (3), pp. 1059-1066. Date of Electronic Publication: 2020 Sep 07 (Print Publication: 2020).